Literature DB >> 12458261

Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.

Hilary Calvert, Duncan I Jodrell, James Cassidy, Adrian L Harris.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12458261      PMCID： PMC1124759          DOI： 10.1136/bmj.325.7375.1302/a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Efficacy, safety, and cost of new anticancer drugs.

Authors:  Silvio Garattini; Vittorio Bertele
Journal:  BMJ       Date:  2002-08-03

3.  Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  R B Forbes; A Lees; N Waugh; R J Swingler
Journal:  BMJ       Date:  1999-12-11

Review 4.  Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

Authors:  J M Nabholtz; K Tonkin; M Smylie; H J Au; M A Lindsay; J Mackey
Journal:  Expert Opin Pharmacother       Date:  2000-01       Impact factor: 3.889

5.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

6.  How many deaths have been avoided through improvements in cancer survival?

Authors:  M A Richards; D Stockton; P Babb; M P Coleman
Journal:  BMJ       Date:  2000-04-01

7.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

8.  The cost effectiveness of preoperative autologous blood donations.

Authors:  J Etchason; L Petz; E Keeler; L Calhoun; S Kleinman; C Snider; A Fink; R Brook
Journal:  N Engl J Med       Date:  1995-03-16       Impact factor: 91.245

9.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

Review 10.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.

Authors:  J Sandercock; M K B Parmar; V Torri; W Qian
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.